How to Determine Product Classification for Overseas Registration of Active Medical Devices?

Key Summary

Determining the product classification for overseas registration of active medical devices directly influences the registration pathway, depth of technical documentation, clinical evaluation requirements, and post-market regulatory obligations. Many companies first assess risk level according to domestic Chinese medical device classification rules. However, for overseas registration, you must first confirm whether the target country regulates the device as a medical device, and then apply that country's or region's classification rules to establish the risk class and registration route. Common classification factors include intended use, contact duration, form of energy output, whether the device is implanted or invasive, and whether it incorporates a drug or biological component.

Companies should prioritize evaluating whether existing NMPA registration files, CE technical documentation, FDA 510(k) or PMA submissions, ISO 13485 quality system documents, and MDSAP audit results can be reused. Then, supplement local requirements such as labeling, language, testing standards, and clinical evidence. Common pitfalls include neglecting classification boundaries, which can lead to choosing the wrong registration pathway, or directly substituting domestic classification for the target country's classification, resulting in significant deviations in dossier preparation.

It is recommended that companies complete classification confirmation and gap analysis before the project starts, establish a core technical document library, clarify the responsibilities of local agents and authorized representatives, and plan for post-market periodic updates and change notifications. This approach reduces the risk of redundant work and deficiency corrections across multiple countries.

Applicable Scenarios and Core Questions

For active medical device companies entering GHWP member states, Southeast Asia, the Middle East, Latin America, and other markets, product classification determination is a priority. Classification decides whether the registration route is notification, listing, or pre-market approval. It also affects technical file depth, quality system audit requirements, the extent of clinical evaluation or clinical evidence, label and instruction language requirements, the authorization method for local representatives, and post-market adverse event reporting obligations.

Many companies intend to replicate their domestic NMPA registration files or in-progress applications directly for overseas markets. However, each country or region has independent medical device classification rules. For example, the US FDA uses a product classification database, the EU applies MDR rules, ASEAN follows the ASEAN Medical Device Directive with supplementary national rules, and Middle Eastern and Latin American countries differ as well. Even if a product works on the same principle, it may be classified into different risk classes in different countries, resulting in completely different registration pathways.

Therefore, companies need to build a reusable classification decision framework rather than starting from scratch for each market. This framework should cover regulatory scope determination, risk class determination, assessment of existing document reusability, localization conversion, local agent responsibilities, and post-market maintenance.

Registration Classification Decision Logic

Step 1: Confirm the Regulatory Scope

First, determine whether the product falls within the target country's medical device regulatory definition. Some devices are regulated as medical devices in certain countries but may be classified as personal care devices, health management tools, or communication devices elsewhere. For example, a blood pressure measurement app may be considered medical device software in most countries but only a lifestyle tool in some regions. Review the target country's medical device definition, intended use claims, and officially published classification guidance.

Step 2: Determine Risk Class, Registration Route, and Applicant

Target countries generally classify medical devices into low, medium, and high risk. For active devices, common classification criteria include energy output type, whether the device is invasive, implantable, delivers medication to the patient, or includes software functions. Confirm whether the applicant must be the local manufacturer or an overseas manufacturer applying through a local agent, as this affects file submission and certificate holder arrangements.

Step 3: Assess Reusability of Existing Documentation

Evaluate whether existing NMPA, CE, FDA, ISO 13485, MDSAP, or other market documents can be reused. For instance, if you have CE technical files, the risk management report, safety test report, and EMC test report can often serve as core evidence. If you have an FDA 510(k), most preclinical test data may be reusable. However, note that different countries adopt different standard versions, testing requirements, label languages, and clinical evaluation policies; direct copying is not acceptable.

Step 4: Confirm Localization and Post-Market Requirements

Confirm technical documentation, performance verification, risk management, clinical evaluation or clinical evidence, labeling, local agent, authorized representative, and post-market obligations. For active devices, the technical file typically includes product description, specifications, labels, instructions for use, risk analysis, design verification, safety and EMC test reports, software verification, sterilization or cleaning validation (if applicable), and clinical evaluation reports. Also check whether local language instructions are needed, whether physical submission by a local representative is required, and whether periodic renewal or annual fees apply.

Documentation and Evidence

Core documents for overseas registration of active medical devices include product technical files, quality management system certificates, test reports, clinical evaluation files, and labeling.

• Product Technical File: A complete description of the device's design principles, composition, key components, software version, and intended use. The risk analysis report should adhere to ISO 14971 or an acceptable risk management standard, covering electrical safety, mechanical safety, electromagnetic compatibility, cybersecurity, and foreseeable misuse.
• Quality Management System Certificate: Usually an ISO 13485 certificate. Some countries accept MDSAP certificates; others require an on-site audit or QMS audit questionnaire. Without a QMS certificate, companies must establish the quality system before initiating registration.
• Test Reports: Performance verification and safety test reports, preferably from a laboratory with recognized accreditation. Testing is often based on IEC 60601 series standards. Some countries accept CE and FDA reports, but may require additional statements explaining local specification differences.
• Clinical Evaluation or Clinical Evidence: Determined by the device risk class. Low-risk devices may only require literature review or equivalence comparison; medium- and high-risk devices may require local clinical trials or real-world data studies. Confirm early whether the target country accepts overseas clinical data.
• Labeling and Instructions for Use (IFU): Must comply with the target country's language, units, and warning symbol requirements. The IFU should include intended use, contraindications, warnings, precautions, maintenance, and troubleshooting. All content must be consistent with the registration file.
• Local Agent and Authorized Representative Information: Include the agency agreement, power of attorney, agent qualification evidence, and contact details. During registration, regulatory authorities typically communicate with the company through the local agent.

Common Mistakes

• Directly substituting domestic classification for the target country's classification, leading to an incorrect registration route. A domestic Class III active device may be only Class II in some countries, and vice versa.
• Ignoring the impact of intended use on classification. The same hardware device, if promoted as a therapeutic device, may be classified at a higher risk level than if it is only used for monitoring.
• Assessing a hardware-software combination product's software classification separately, while neglecting the software's cumulative impact on the overall product risk class.
• Failing to perform a gap analysis of existing documents and simply translating files, causing unnecessary repeated testing and cost overruns.
• Neglecting the ongoing responsibilities of the local agent and authorized representative. When a representative changes, certificates may become invalid if not updated with the regulator in time.
• Not planning for post-market change notifications. Software updates or hardware upgrades submitted without a timely change application can lead to certificate revocation or product sales suspension.

Preparedness Checklist for Companies

• Confirm the target country's official guidance and classification database, and complete a product classification boundary analysis.
• Organize information on the product's intended use, working principle, technical specifications, and software functions, and create a classification rationale document.
• Inventory existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation, and identify items that can be directly reused versus those requiring localization.
• Prepare the risk management report, safety test report, EMC test report, and software verification report, confirming report validity and laboratory accreditation.
• Define the clinical evaluation or clinical evidence strategy, and prepare literature search reports or clinical trial protocols as necessary.
• Designate local agents and authorized representatives, sign formal agreements, and retain qualification documents.
• Plan for label and IFU translation, localization review, and final version control procedures.
• Establish a post-market surveillance and change management process, including adverse event reporting, vigilance, annual updates, and significant change notifications.

AIMEILI's Perspective

The most common misjudgment in overseas classification is assuming that because a product has obtained CE or FDA clearance, other countries will adopt the same classification. In reality, there is no uniform cross-system classification correspondence, and even within the same alliance, boundary disputes can occur. Companies should have the regulatory team or an external consultancy conduct a regulatory scope confirmation and risk class determination for each target market before project initiation and document it in a written classification memorandum.

At the beginning of a project, classification consensus and gap analysis are the most valuable steps. We recommend selecting one or two target markets as pilot projects, completing a full technical file framework, and then replicating it to other markets. This approach allows you to identify documentation gaps from the first market's review comments and reduce the cost of repeated deficiencies later.

Regarding document reuse, ISO 13485 system files, IEC 60601 series safety and EMC test reports, and risk analysis reports are generally reusable. However, clinical evaluation, labeling, restricted substance requirements, and local language versions must be localized. Do not blindly assume that an original CE report for a Class III active device can be directly converted to other markets; some countries impose additional review requirements on reports submitted by Chinese companies.

Why are local agents, certificate control, changes, and renewals important? Because many companies discover that the nominal certificate holder is the local agent. If the agent changes or cannot cooperate with renewals, the product may be forced out of the market. Certificate control should be clearly agreed; all original files should remain with the company, and the agent should only handle submissions and communications. Change and renewal require time planning and budget; otherwise, market access can be lost by missing renewal deadlines.

The key to reducing duplication and rectification risks in multi-country registration is to establish a two-tier structure: a 'core technical document library' plus 'country-specific differences.' Prepare a complete technical dossier using a globally accepted format, and then develop a difference rationale, local language labels, and special reports for each country. This way, even when entering a new country, only localized differences need to be addressed.

Frequently Asked Questions

How should the contribution of software be assessed in active device classification?

If the device contains standalone software or embedded software, determine whether the software has a medical purpose and whether it drives therapeutic or diagnostic outputs. In general, embedded software used for device control is classified together with the whole device and cannot independently change the risk class. However, standalone medical software (SaMD) must be classified separately according to its own software classification rules, and cybersecurity and update impacts may also need to be evaluated.

Can CE technical documentation be used directly for registration in Southeast Asian countries?

CE technical files can serve as the core base documentation, but they cannot be submitted directly. Southeast Asian countries generally accept IEC 60601 series test reports, but they have their own requirements regarding report validity, language versions, clinical evaluation policies, and local agents. You will need to convert CE files into the local Common Submission Dossier Template (CSDT) format, usually supplementing with a local declaration of authorization, declaration of conformity, and translated labels and IFUs. You should also confirm whether local testing or a local review is required.

If a product is classified as low-risk in the target country, is clinical evaluation still required?

Not necessarily. Low risk does not exempt you from clinical evaluation. Many countries still require a literature review, equivalence comparison, or descriptive evidence for low-risk medical devices to demonstrate safety, performance, and a favorable benefit-risk profile. Only products with minimal risk may be exempt from submitting clinical evaluation evidence, but a clinical rationale must usually be included in the technical documentation.

Can the same entity serve as local agent and authorized representative for multiple countries?

Yes, but you must confirm whether each target country allows an overseas manufacturer to designate the same entity as local agent. If allowed, you may choose a regional agent covering multiple countries for easier management of certificates and communications. However, agent qualifications, power-of-attorney formats, local registered addresses, and legal liability requirements vary by country, so you cannot simply reuse the same agency agreement. The agreement should clearly define certificate control, data access rights, and change coordination obligations.